Reply  by Reeps, Christian et al.
LETTERS TO THE EDITORRegarding “Increased 18F-fluorodeoxyglucose
uptake in abdominal aortic aneurysms in positron
emission/computed tomography is associated with
inflammation, aortic wall instability, and acute
symptoms”
The excellent study by Reeps et al demonstrated increased aor-
tic 18F-fluorodeoxyglucose (18F-FDG) metabolism measured by
positron emission tomography (PET) CT scans in patients with
asymptomatic abdominal aortic aneurysms (AAAs) compared with
healthy controls (mean maximum standard uptake values [SUVmax],
3.5 0.6 vs 3.0 0.5, respectively; P .05).1 Furthermore, patients
with symptomatic AAAs had significantly higher focal 18F-FDG
metabolism compared with those individuals with asymptomatic
AAAs (mean SUVmax, 7.5  0.3 vs 3.5  0.6, respectively; P 
.001).1 As the authors themselves concluded, these results suggest
that “18F-FDG PET CT imaging might be a new approach to
identify AAAs at risk before acute aneurysm onset”.1 These findings
support (and complete) the results of an earlier study.2
Based on international guidelines,3 the main criterion for
surgical treatment of AAAs is their size (5.5 cm); however, some
AAAs rupture when they are small.1,4 A marker for AAA wall
instability (such as 18F-FDG) could help identify patients at great-
est risk for AAA rupture.1,2 Besides this, however, it would be
interesting to determine whether 18F-FDG has the potential to act
as a predictor of AAA growth and instability. This could be
accomplished by recruiting patients with small (3.0-4.5 cm) AAAs
and having them undergo a baseline 18F-FDG PET CT scan.
These patients should then be followed-up by ultrasound to record
AAA expansion. By repeating the 18F-FDG PET CT scan after a
certain period of time (eg, 3 years), it may be possible to determine
if 18F-FDG uptake is associated with AAA expansion. Such an
association may hold implications for the earlier surgical manage-
ment of some AAA patients (and/or the conservative management
of others). In addition, such an association would help evaluate the
effect of conservative measures on AAAs (eg, with statins).5
Kosmas I. Paraskevas, MD, FASA
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In our manuscript “Increased 18F-fluorodeoxyglucose uptake
in abdominal aortic aneurysms in positron emission/computed
tomography is associated with inflammation, aortic wall instability,
and acute symptoms,” we demonstrated that fluorodeoxyglucose
(FDG)-uptake may be a marker of aortic wall instability in abdom-
inal aortic aneurysm (AAA) patients. In particular, assessment of
FDG-uptake may be useful to detect small aneurysms with high
risk for progression or rupture. To prove the real prognostic value
of positron emission/computed tomography (PET/CT) in this
context, a large prospective study with a well-defined patient
collective would be useful with the best statistical power as sug-
gested in the letter of K. I. Paraskevas. However, as commonly
known in AAA formation, periods of rapid progression are inter-
rupted by periods of stability. Consequently, the glucose metabo-
lism may not be continuously elevated, and each patient needs to
be scanned repeatedly, leading to excessive radiation exposure. In
patients with low risk of rupture, this additional and potentially
harmful radiation exposure seems unacceptable for ethical reasons.
In contrast, patients with higher risk of rupture need to undergo
early surgery. Therefore, a prospective study should focus on the
small group of patients deemed as unfit for AAA repair. Alterna-
tively, our study group tried to answer this question retrospec-
tively, and we initiated a retrospective study about the FDG-uptake
in cancer patients with concomitant AAA. Unfortunately, in this
patient collective, prevalence of AAA was under-represented re-
sulting in an undersized study cohort. Moreover in this study
group, the follow-up period was limited by the short survival rates
of these cancer patients. Therefore, a retrospective multicenter
study might be helpful to assess the prognostic value of increased
FDG up-take in small AAA without the potential harms of addi-
tional radiation exposure. Alternatively, the correlation of glucose
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Regarding “Nutrition impacts the prevalence of
peripheral arterial disease in the United States”
In the article by Lane et al titled “Nutrition impacts the
prevalence of peripheral arterial disease in the United States,”1 the
authors showed that peripheral arterial disease (PAD) could be in
part caused by nutritional behavior. High consumption of vitamin
C, folate, and w-3 fatty acids might prevent this disease, which is
mainly the result of atherosclerosis. Many risk factors also explain
atherosclerosis such as tobacco, dyslipidemia, age, hypertension,
and diabetes. PAD shared the same risk factors with coronary heart
disease (CHD) and some ischemic strokes. It is well known that
nutrition plays a role in CHD development as De Lorgeril and
colleagues demonstrated.2 Good eating habits diminish the risk of
new heart infarct. Nutrition also plays a role in some ischemic
stroke as established by Fung and colleagues.3 So, ischemic vascu-
lar disease (including CHD, PAD, and some ischemic strokes) is in
part due to nutrition. Thus, it will be interesting to evaluate diet in
patients with vascular risk and to give them diet advice in addition
to the best medical or/and the best surgical treatment. This diet
advice might be: Low saturated fatty acids intake, high w-3 poly
unsaturated fatty acids, and high fruit and vegetables intake which
may reduce the risk of vascular disease. A short food-frequency
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Reply
We greatly appreciate the editorial response to our article and
the insightful comments. As the letter has pointed out, previous
authors have suggested that improved nutrition could reduce the
incidence of ischemic heart disease and stroke. The intention of our
study was to explore the associations between nutrient intake and
the prevalence of peripheral vascular disease (PVD).
We wish to highlight the magnitude of the poor nutrition
among Americans with PVD (ankle-brachial index 0.9), num-
bering 16.5 million people. The use of National Health and
Nutrition Examination Survey, with its stratified sampling design,allowed us to make this extrapolation. In addition, we found that
most of these participants reported nutrient intakes far below the
United States Recommended Daily Allowances. This suggests
considerable improvement could be made by instituting preventa-
tive public health measures.
We found that improved consumption of certain nutrients was
associated with a reduced prevalence of PVD, after adjustment for
traditional cardiovascular risk factors. These include antioxidants (vi-
tamins A, C, and E), B vitamins (folate and B6), and polyunsaturated
fatty acids (-3). This would suggest that these nutrients could be
targeted in clinical trials aimed at reducing the risk of PVD.
Many prospective observational studies and randomized clin-
ical trials have previously examined the role of nutrition in PVD.
These studies have been discussed in the article, and their results
have not been consistent. Therefore, we do not wish to overstate
the results of our study. Because this is an observational study, it
cannot be used to determine causality or to make specific dietary
recommendations.
The authors believe that nutritional recommendations should
be made as a result of randomized prospective trials. We think this
recommendation should include a balanced combination of nutri-
ents and healthy foods, such as fruits, vegetables, and lean proteins
containing polyunsaturated fatty acids. This type of heart-healthy
diet could have considerable impact in the reduction of ischemic
heart disease, stroke, and PVD, because they all result from the
process of atherosclerosis.
John S. Lane, MD
Division of Vascular Surgery
Center for Health Policy Research
University of California, Irvine
Irvine, Calif
doi:10.1016/j.jvs.2008.12.031
Regarding “Suboptimal use of statin therapy in
elderly patients with atherosclerosis: A
population-based study”
In a large population study of elderly patients (mean age 77.1
years) from Canada with symptomatic atherosclerosis, Dr Al-Omran
and colleagues demonstrated an increase in statin therapy over time
among the patients, from 9.8% in 1995 to 55.3% in 2004.1 They
suggest that the use of statins in this elderly population was still
suboptimal and they call for action to further increase statin use in
order to decrease cardiovascular disease. However, evidence suggests
that statin use in the elderly is a double-edged sword2 and might do
more harm than good, or at best trade one disease for another.
The PROspective Study of Pravastatin in the Elderly at Risk
(PROSPER) is the only randomized trial that specifically investi-
gated the benefits of statin therapy in an elderly population (mean
age was 75 years at trial entry).2 The trial subjects had prevalent
cardiovascular disease or were at high risk for cardiovascular disease
and were randomized to pravastatin 40 mg daily or placebo for the
3.2 year trial duration. Cancer incidence increased significantly in
subjects randomized to pravastatin, and the increase in cancer
mortality equaled in magnitude to the decrease in coronary heart
disease death in the pravastatin group. All cause mortality was
unchanged, suggesting that statin therapy in this high-risk elderly
population changed the cause, but not the incidence of death.
Statins are immunosuppressive and have been shown to in-
crease the peripheral numbers and functionality of regulatory
T-cells (Tregs) in vivo by increasing the activity of the transcription
factor forkhead box P3.3 Even though this is thought to stabilize
atherosclerotic plaque by reducing effector T-cell responses within
the atheroma,4 it may impair the host antitumor response by
suppressing tumor-specific effector T-cell functions, resulting in
immune tolerance to cancer cells.5 Not unexpectedly, the numbers
